AstraZeneca on Tuesday announced it has temporarily suspended global trials of a possible COVID-19 vaccine after one of the volunteers experienced a "potentially unexplained illness."
The pharmaceutical company is testing Oxford University's vaccine in the U.S., United Kingdom, Brazil, and South Africa. It is one of three potential coronavirus vaccines now in final Phase 3 trials in the U.S.
It is standard procedure for experimental vaccine trials to pause in order to determine if the vaccine is causing serious reactions in volunteers. AstraZeneca said in a statement that during large trials, "illnesses will happen by chance but must be independently reviewed to check this carefully. We are working to expedite the review of the single event to minimize any potential impact on the trial time lines. We are committed to the safety of our participants and the highest standards of conduct in our trials."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Earlier in the day, AstraZeneca and eight other companies, including Johnson & Johnson and Moderna, signed a pledge promising not to push for early government approval of any coronavirus vaccine.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.